A phase Ib/II trial [111] showed that this combination could be a promising treatment for patients with EGFR-mutated, MET-dysregulated NSCLC, particularly MET-amplified disease (ORR of 47% in patients with a MET gene copy number ≥ 6). Here, MET is linked to non-small cell lung carcinoma.